Takeda Pharmaceutical Company Limited (FRA:TKD)

Germany flag Germany · Delayed Price · Currency is EUR
31.14
-0.22 (-0.70%)
At close: Feb 20, 2026
Market Cap50.11B +25.0%
Revenue (ttm)24.25B -2.5%
Net Income613.43M -45.7%
EPS0.38 -45.9%
Shares Outn/a
PE Ratio81.69
Forward PEn/a
Dividend1.17 (3.77%)
Ex-Dividend DateSep 29, 2025
Volume82
Average Volume213
Open31.56
Previous Close31.36
Day's Range31.14 - 31.56
52-Week Range22.45 - 31.77
Betan/a
RSI68.89
Earnings DateJan 29, 2026

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]

Industry Pharmaceutical Preparations
Founded 1781
Employees 47,455
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol TKD
Full Company Profile

Financial Performance

In fiscal year 2025, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY Financial Statements